Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited's Active Pharmaceutical Ingredient (API) manufacturing facility, Unit II, situated at Raichur in Karnataka state has undergone a GMP inspection by PMDA, Japan starting 29th August 2023.

The inspection has concluded successfully on 1st September 2023 without any critical/major observation. The facility is involved in manufacturing various oncology and non‐oncology APIs.

The company remains committed to maintain the GMP status and quality standards as per the expectations and standards of Global Regulatory Authorities.